Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Goes Overbought

[[tagnumber 0]][[tagnumber 1]]Ever since Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) announced intentions to list its common stock on the Tel–Aviv Stock Exchange (TASE) on Aug. 24 in an effort to increase its exposure to a country where it could find potential investor support for its precision diagnostic tools, NAVB stock has been riding high on the New York Stock Exchange. SO high that it has now gone overbought and fallen under risk of going south again.[[tagnumber 2]] [[tagnumber 0]][[tagnumber 4]]It barely took two weeks for the application to meet with success and NAVB started trading on the TASE under the same ticker. According to CEO Rick Gonzales, the TASE listing ‘will facilitate access to emerging international capital market”, as well as “further diversify shareholder base in a region with growing biotech and pharma industries”, which practically means a wider investment base if need be. From a long–term perspective, this decision will have two important implications. First, it gives the company the potential to popularize its therapeutic methods in a country with highly qualified medical workforce when it comes to treating life–threatening, cancer–related diseases. Second, the company will bear no additional regulatory burden because it is simply not required to file any additional reports other than the ones it already files with the U.S. Securities and Exchange Commission. This benefit is provided under Israel’s Dual Listing Law.[[tagnumber 2]] [[tagnumber 0]]NAVB recently recorded its highest quarterly revenue as it raked in $2.9 million during the second quarter of 2015, thus marking a significant improvement over the preceding three quarters on record. However, the same goes for its net loss of $9.7 million when compared to the three negative earnings reports beforehand. That being said, NAVB seems to have $4 of current assets against each dollar of short–term debt, which allow for a few cloudless quarters ahead.[[tagnumber 2]] [[tagnumber 0]]The real ordeal NAVB has been facing for quite a while, however, is its long–term debt, which practically doubled in the last quarter alone, clocking in at a little less than $59 million. That is something management will need to deal with if they want to put the stock on the path towards continual growth on the charts.[[tagnumber 2]]